Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Panacea Biotech Gains 6%; BSE HEALTHCARE Index Up 0.9%
Thu, 12 Sep 14:32

Panacea Biotech Gains 6%; BSE HEALTHCARE Index Up 0.9%Image source: hudiemm/www.istockphoto.com

Panacea Biotech share price has zoomed 6% and is presently trading at Rs 298.0.

Meanwhile, the BSE HEALTHCARE index is at 44,202.1 (up 0.9%).

Among the top gainers in the BSE HEALTHCARE index today are FDC (up 8.0%) and MAX HEALTHCARE INSTITUTE (up 4.7%).

GRANULES INDIA (down 16.8%) and ALEMBIC PHARMA (down 2.0%) are among the top losers today.

Over the last one year, Panacea Biotech has moved up from Rs 135.1 to Rs 298.0, registering a gain of Rs 162.9 (up 120.6%).

On the other hand, the BSE HEALTHCARE index has moved up from 28,436.8 to 44,202.1, registering a gain of 55.4% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 132.9%), SUVEN PHARMACEUTICALS (up 128.5%) and Glenmark Pharma (up 114.2%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 82,499.9 (up 1.2%).

The top gainers among the BSE Sensex today are Bharti Airtel (up 3.9%) and NTPC (up 2.8%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.

In the meantime, NSE Nifty is at 25,251.8 (up 1.3%). Bharti Airtel and Hindalco are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 67,127.1 to 82,499.9, registering a gain of 15,372.8 points (up 22.9%).

Panacea Biotech Financial Update...

Panacea Biotech net profit fell 244.6% YoY to Rs -159 million for the quarter ended June 2024, compared to a profit of Rs 110 million a year ago. Net sales declined 10.4% to Rs 1,157 million during the period as against Rs 1,292 million in April-June 2023.

For the year ended March 2023, Panacea Biotech reported 103.1% decrease in net profit to Rs -337 million compared to net profit of Rs 10,783 million during FY22. Revenue of the company fell 30.4% to Rs 4,599 million during FY23.

The current Price to earnings ratio of Panacea Biotech, based on rolling 12 month earnings, stands at -64.1.


Equitymaster requests your view! Post a comment on "Panacea Biotech Gains 6%; BSE HEALTHCARE Index Up 0.9%". Click here!